Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Peter Ackerman, MD

Project Physician Lead, Research and Development

Contact peter.x.ackerman@viivhealthcare.com

With nearly 10 years of experience in new drug development of novel therapies for HIV and hepatitis, Dr. Peter Ackerman brings a wealth of knowledge, insight, and leadership to ViiV Healthcare’s research and development team. With achievements in clinical medicine, research, teaching, and public service, Peter has a distinguished publication history and is recognized for his outstanding commitment and contributions to education, clinical care, and research on behalf of children and adults. His clinical and research skills add keen insight and a fresh approach to ViiV to help uncover innovative medicines to better serve the HIV community.

Current Role

Peter joined ViiV Healthcare in 2016 as a Project Physician Lead. In this role, he is responsible for clinical strategy, safety monitoring, and clinical data interpretation/reporting for the adult and pediatric programs for fostemsavir, a novel, first-in-class HIV-1 attachment inhibitor; and combinectin, a novel HIV-1 injectable biologic.

Experience

Prior to joining ViiV, Peter spent five years as a Director and Medical Monitor in Virology, Global Clinical Research for Bristol-Myers Squibb (BMS) in Wallingford, Connecticut. His responsibilities included clinical trial conduct and safety monitoring as well as interpretation and reporting of clinical data across the adult and pediatric programs for several investigational agents: fostemsavir (now acquired by ViiV), daclatasvir (an anti-HCV direct-acting antiviral NS5a inhibitor), and entecavir (an anti-HBV antiviral nucleoside analogue). While at BMS, Peter was honored with selection for the Next Generation Leadership Program, a company-wide development program for employees who have demonstrated leadership and performance skills. He was also appointed Co-Lead and Developer on a project that introduced data visualization for clinicians as a means to enhance clinical trial safety monitoring.

Prior to his experience in industry, Peter worked as a clinician providing primary care in Internal Medicine and Pediatrics for several years at a community health center in Tampa, Florida. A notable public service contribution was Peter’s two-year post-baccalaureate commitment as a Community Activist/Team Leader in Boston, where he developed and led community service projects dedicated to addressing low-income housing and homelessness issues.

Education

Peter received his MD in 2002 from Jefferson Medical College (Sidney Kimmel Medical College) in Philadelphia, and completed a Residency in Internal Medicine/Pediatrics at the University of Missouri Hospital and Clinics in Columbia and a Fellowship in Infectious Diseases at Brown University in Providence, Rhode Island. His undergraduate work was at Duke University, where he received a BA in Political Science. Peter is board-certified in Internal Medicine, Pediatrics, and Infectious Diseases.

Personal Interests

Peter lives in Madison, Connecticut with his wife Beth, and their four children.

Connect with our Medical Experts

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Receive Medical Updates

Signup to receive email updates with the latest ViiV medical information in your areas of interest

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert

Find my ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1-888-226-8434

Weekdays from 8 AM to 6 PM ET (6 AM – 3 PM PT)

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch